Professional Documents
Culture Documents
Septic shock
Hamed Rashad
Septic Shock
• Septic shock- once a uniformly fatal
condition with 100% mortality.
Platelets
Jaundice PT/APTT
Enzymes Protein C
Albumin D-dimer
PT
Septic Shock
Septic shock = sepsis induced hypotension
despite adequate fluid resuscitation along with
perfusion abnormalities that may include, but are
not limited to :
lactic acidosis,
oliguria, or
an acute alteration in mental status.
– Hypotension = systolic BP of <90 mmHg or a reduction
of ≧40 mmHg from baseline in the absence of other
causes for the fall in blood pressure.
Placebo N=840
40
30
20
10
0
Lung Intra- Urinary Blood Skin Other
Abdominal Tract
Site of Infection
Changes in the Documented Causes of Sepsis
Martin NEJM 2003
Why do people die from Sepsis?
• Very few organisms produce toxins that cause
death directly
– Diptheria
– Tetanus, botulism
– Pseudomonas aeruginosa ?
Cytokine Storm ?
Bad side
Genetic predisposition ARDS
to immune hyperstimulation MODS
Pathophysiology
• What ‘type of shock’ is septic shock?
Septic shock has features of :
– Hypovolemic shock
– Cardiac shock
– Distributive shock.
Pathophysiology of septic shock
and SIRS
• The hemodynamic derangements observed
in septic shock and SIRS are due to a
complicated cascade of inflammatory
mediators released in response to infection,
inflammation, or tissue injury.
Pathophysiology of septic shock
and SIRS
• Tumor necrosis factor-alpha (TNF-alpha),
interleukin (IL)-1b, and IL-6 act
synergistically with other cytokines and
phospholipid-derived mediators to produce
the complex alterations in vascular and
myocardial function, which leads to
maldistribution of blood flow
Pathophysiology:
• Decreased tissue perfusion results primarily
from :
• 1-arterial hypotension due to reduction in
SVR.
• 2-reduction in effective circulating plasma
volume due to: a-- decrease in venous tone
and subsequent pooling of blood in venous
capacitance vessels.
Pathophysiology:
b-loss of intravascular volume into the interstitium
due to increased capillary permeability also
occurs.
• Finally, primary myocardial dysfunction often is
present as manifested by ventricular dilatation,
decreased ejection fraction (despite normal stroke
volume and cardiac output), and depressed
ventricular function curves
Pathogenesis of Severe Sepsis
Infection
Microbial Products
(exotoxin/endotoxin)
Cellular Responses
Coagulopathy/DIC
Vascular/Organ System Injury
Death
Severe Sepsis: The Final Common Pathway
Cytokine storm
Endothelial Dysfunction and
Microvascular Thrombosis
Hypoperfusion/Ischemia
Death
Clinical Manifestations.
• The Continuum of infection
to
MODS and Death
(Clinical Definition)
History:
Figure B, page 948, reproduced with permission from Dellinger RP. Cardiovascular
management of septic shock. Crit Care Med 2003;31:946-955.
EGDT first 6
hours in ER
500ml bolus of
colloid every 30min
Dobutamin started at
2.5 ug/kg/min,
increase by
2.5ug/kg/min every
30 min, or until
maximal dose
20ug/kg/min given
Decrease
dobutamin dose
if MAP
>65mmHg or
HR> 120bpm
Initial Resuscitation (2008)
Initial resuscitation (first 6 hrs)
Begin resuscitation immediately in patients with hypotension or elevated
serum lactate 4 mmol/L; do not delay pending ICU admission (1C)
Resuscitation goals (1C)
CVP 8–12 mm Hg a
Mean arterial pressure 65 mm Hg
Urine output 0.5 mL/kg/hr
Central venous (superior vena cava) oxygen saturation 70% or mixed
venous 65%
If venous oxygen saturation target is not achieved (2C)
Consider further fluid
Transfuse packed red blood cells if required to hematocrit of 30%
and/or
Start dobutamine infusion, maximum 20 μg/kg/min
Diagnosis
• Obtain appropriate cultures before starting antibiotics provided this
does not significantly delay antimicrobial administration (1C)
– Obtain two or more BCs
– One or more BCs should be percutaneous
– One BC from each vascular access device in place 48 hrs
– Culture other sites as clinically indicated
• Perform imaging studies promptly to confirm and sample any
source of infection, if safe to do so (1C), (ex. Sonography suitable,
transport outside unit may be dangerous)
Antibiotic Therapy (2008)
• Begin intravenous antibiotics as early as possible and
always within the first hour of recognizing severe
sepsis (1D) and septic shock (1B)
– In the presence of septic shock, each hour delay in
achieving administration of effective antibiotics is
associated with a measurable increase in mortality
• Broad-spectrum: one or more agents active against
likely bacterial/fungal pathogens and with good
penetration into presumed source (1B)
– Watch out MRSA in some communities and healthcare
settings
Antibiotic Therapy (2008)
• Reassess antimicrobial regimen daily to
optimize efficacy, prevent resistance,
avoid toxicity, and minimize costs (1C)
• Consider combination therapy in
Pseudomonas infections (2D)
• Consider combination empiric therapy
in neutropenic patients (2D)
Antibiotic Therapy (2008)
• Combination therapy 3–5 days and de-
escalation following susceptibilities (To
single therapy) (2D)
• Duration of therapy typically limited to 7–10
days; longer if response is slow or there are
undrainable foci of infection or immunologic
deficiencies (1D)
• Stop antimicrobial therapy if cause is found
to be noninfectious (1D)
Optimum therapy of Sepsis and Shock
• Antibiotics remain the most critical choice to be made
– TIMELY-reduces mortality
– EFFECTIVE, BROAD SPECTRUM-reduces mortality
– DIFFERENT antibiotics for different patients
– P. aeruginosa continues to be associated with highest mortality
– Resistance issues need to be kept in mind
– A large number of patients with the sepsis syndrome will not have an
organism cultured but should be treated with antibiotics
• Prevent the development of septic shock - fluids and
Right antibiotics
Antibiotic Choices
• Given the world wide resistance issues the most effective
antibiotic choices to cover gram negatives would be
– Fourth generation cephalosporins ± aminoglycoside
(Geographic location)
– Carbapenems ± aminoglycoside (Pseudomonas
resistance during therapy of Lung infections)
– Pip-Tazobactam + an aminoglycoside (Esbl
resistance)
• If the incidence of MRSA is high and gram positive
coverage is needed, add an anti Staphylococcal agent
--Vanco, Teicoplanin
Choosing the RIGHT antibiotic in Sepsis
2002 opinion
Source identification and control
(2008)
• A specific anatomic site of infection should be
established as rapidly as possible (1C) and within
first 6 hrs of presentation (1D)
– E.g., necrotizing fascitis, diffuse peritonitis, cholangitis,
intestinal infarction)
• Formally evaluate patient for a focus of infection
amenable to source control measures (e.g. abscess
drainage, tissue debridement, removal of a potentially
infected device, or the definitive control of a source
of ongoing microbial contamination) (1C)
Source identification and control
(2008)
• Implement source control measures as soon as
possible following successful initial resuscitation
(1C) (exception: infected pancreatic necrosis, where
surgical intervention is best delayed) (2B)
• Choose source control measure with maximum
efficacy and minimal physiologic upset (1D)
– e.g., percutaneous rather than surgical drainage of an
abscess
• Remove intravascular access devices if potentially
infected (1C)
– Prompt remove after other vascular access had been
established
:
Fluid Therapy (2008)
Figure 2A, page 867, reproduced with permission from Annane D, S ébille V, Charpentier C, et
al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in
patients with septic shock. JAMA 2002; 288:862-871
Human Activated Protein C
Endogenous Regulator of Coagulation
25
reduction
20
in mortality
15 Placebo Drotrecog
10 in alfa
(n-840)
(activated
5
) (n=850)
0
Adapted from Table 4, page 704, with permission from Bernard GR, Vincent JL, Laterre PF, et al.
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med
2001; 344:699-709
Mortality and APACHE II Quartile
118:80
50
Placebo
45
Mortality (percent)
40 Drotrecogin
35
58:48
30
57:49
25
20
15
26:33
10
5
0
1st (3-19) 2nd (20-24) 3rd (25-29) 4th (30-53)
APACHE II Quartile
*Numbers above bars indicate total
Adapted from Figure 2, page S90, with permission from Bernard GR. Drotrecogin alfa (activated)
(recombinant human activated protein C) fordeaths
the treatment of severe sepsis. Crit Care Med 2003;
31[Suppl.]:S85-S90
Mortality and Numbers of Organs Failing
60
50
Percent
Mortality
40
30
20
Placebo 10
Drotrecogin
0
1 2 3 4 5
Number of Organs Failing at Entry
Adapted from Figure 4, page S91, with permission from Bernard GR. Drotrecogin alfa (activated)
(recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003;
31[Suppl.]:S85-S90
Blood Product Administration
(2008) Red Blood Cells
25
6 ml/kg
20
12 ml/kg
15
10
5
0
Adapted from Figure 1, page 1306, with permission from The Acute Respiratory Distress
Syndrome Network. N Engl J Med 2000;342:1301-1378
Mechanical Ventilation
of Severe Sepsis
• Maintain mechanically ventilated patients in a
semirecumbent position (head of the bed raised to 45°)
unless contraindicated (to limit aspiration risk and to
prevent the development of VAP) (1B), between 30° and
45° (2C)
Renal Replacement
• Absence of hemodynamic instability
– Intermittent hemodialysis and continuous venovenous
filtration equal (CVVH)
Grade 2B
• Hemodynamic instability
– CVVH preferred --- to facilitate management
of fluid balance in septic patients, no improved in
regional perfusion and survival benefit
Grade 2D
Bicarbonate Therapy
Bicarbonate therapy not recommended to
improve hemodynamics in patients with
hypoperfusion-induced lactic acidemia pH
>7.15
• Will increase Na, fluid overload,
increase lactate and PCO2
Grade 1B